ITRS-GROUP
ITRS Group, leading provider of real-time enterprise monitoring and analytics software to global financial institutions, today announces the launch of its newest product offering, Obcerv.
Amidst rapid digital transformation, modern IT operations have evolved from a traditional on-premises system to increasingly complex hybrid cloud environments. Traditional monitoring no longer addresses the complexities of the modern IT services stack and firms face a growing challenge to centralise data monitoring that can enhance performance, reveal patterns and trends in resource utilisation, and reduce outages.
The launch of Obcerv will introduce end-to-end visibility into infrastructure and applications, and through intelligent alert aggregation, it will identify the most likely source of a problem, enabling users to improve service delivery. Obcerv will act as both a data storage and analytics platform for critical monitoring, allowing users to gain full visibility and ultimately take back control of their systems.
Obcerv simplifies and accelerates traditionally complex monitoring systems with benefits including but not limited to:
- The intelligent correlation of data from multiple data feeds and streams to simplify analysis
- Data compression minimises storage costs, without having to aggregate the data as many tools do, ensuring data fidelity is maintained
- Root cause analysis is accelerated, offering alerts based on commonality, thereby providing context and meaning to alerts
- Unique APIs facilitate full interoperability, Obcerv can store data from other ITRS Group products, but from monitoring tools from other vendors too
Guy Warren, CEO of ITRS Group, said: “Monitoring is often seen as the canary in the coal mine: it may be able to tell you that something is wrong, but too often the message lacks context and meaning. Obcerv will provide IT operators with an understanding around why certain things happen, allowing them to accurately decide the best course of action.
In recent years, modern IT estates have become extremely complex, pushing many monitoring teams to the edge of their capability, leaving them struggling to deliver on uptime and reliability metrics. And with more than half of all firms experiencing at least a day of downtime each year, it is clear that monitoring solutions that are able to match the increasing complexities of the systems they are monitoring is required. Obcerv will not only help firms to gain full visibility across their estates but in doing so, it will enable them to regain control of them.”
For more information, visit www.itrsgroup.com/products/obcerv
About ITRS Group
ITRS Group ensures operational resilience for enterprises engaged in transforming their IT estate for a digital future, as well as the ongoing health of their on-premise, cloud-based or hybrid IT estate. By transforming the mass of raw data on performance, resource usage, and cost, ITRS Group’s solutions can detect and actively prevent problems and maximise cost efficiency, reassuring enterprises that their IT estates are running effectively. With experience in legacy technologies as well as the dynamic environment of cloud-delivery, agile development, and service-based architecture, ITRS Group’s people and software serve more than 4500 clients across industry markets. As new disruptors, new technologies, and new regulations continue to shape the marketplace and change the expectations of consumers, ITRS Group offers a best-in-class service and is a source of confidence for the always-on enterprise.
For more information, visit www.itrsgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220601005091/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
